Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 4/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 4/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19081287 | 0.96 | CYP1A1 (0.37) | CYP1A1CYP1B1CYP1A2MAPK9MAPK14 | |
| SCHEMBL19081178 | 0.94 | CYP1A1 (0.38) | CYP1A1CYP1B1CYP1A2ESR1ESR2 | |
| SCHEMBL19081041 | 0.92 | CYP1A1 (0.39) | CYP1A1CYP1B1CYP1A2MAPK9MAPK14 | |
| SCHEMBL19081323 | 0.92 | CYP1A1 (0.33) | CYP1A1CYP1B1CYP1A2MAPK9MAPK14 | |
| SCHEMBL17944357 | 0.91 | ALOX5 (0.33) | LPLLIPGESR1ESR2 | |
| SCHEMBL19081196 | 0.91 | CYP1A1 (0.34) | CYP1A1CYP1B1CYP1A2 | |
| SCHEMBL19124249 | 0.88 | ALOX5 (0.33) | LPLLIPGESR1ESR2 | |
| SCHEMBL19081242 | 0.87 | CYP1A1 (0.34) | LPLLIPGCYP1A1CYP1B1CYP1A2 | |
| SCHEMBL16170187 | 0.87 | ALOX5 (0.35) | — | |
| SCHEMBL19081337 | 0.86 | CYP1A1 (0.34) | CYP1A1CYP1B1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-02-04 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10553800-B2 | Condensed cyclic compound and an organic light-emitting device including the same | CRY1, CRY2, CCNT1 | LPL 2675/4885LIPG 2901/4885CYP1A1 184/4885 |
| US-20170194572-A1 | CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CCNT1 | LPL 2675/4885LIPG 2901/4885CYP1A1 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.